Literature DB >> 16377672

Resistance of Leishmania donovani to sodium stibogluconate is related to the expression of host and parasite gamma-glutamylcysteine synthetase.

K C Carter1, S Hutchison, F L Henriquez, D Légaré, M Ouellette, C W Roberts, A B Mullen.   

Abstract

Sequencing studies showed that the gamma-glutamylcysteine synthetase (gamma-GCS) heavy chain genes from sodium stibogluconate (SSG)-resistant (SSG-R) and SSG-susceptible (SSG-S) Leishmania donovani strains were identical, indicating that SSG resistance was related to quantitative differences in gamma-GCS expression rather than gene interstrain polymorphisms. In vitro infection of murine macrophages with the SSG-R strain, but not the SSG-S strain, down regulated expression of host gamma-GCS, which would result in a reduction in intramacrophage glutathione (GSH) levels and promote an oxidative intramacrophage environment. This would inhibit, or minimize, the reduction of SSG pentavalent antimony to its more toxic trivalent form. Macrophage studies showed that the SSG-R strain expressed higher levels of gamma-GCS compared to the SSG-S strain, which would result in higher GSH levels, giving increased protection against oxidative stress and facilitating SSG efflux. However a similar differential effect on host and parasite gamma-GCS expression was not obtained when using tissues from infected mice. In this case gamma-GCS expression was organ and strain dependent for both the host and the parasite, indicating that environmental conditions have a profound effect on gamma-GCS expression. Consistent with the proposed mechanism from in vitro studies, increasing tissue GSH levels in the presence of SSG by cotreatment of L. donovani-infected mice with SSG solution and GSH incorporated into nonionic surfactant vesicles was more effective in reducing liver, spleen, and bone marrow parasite burdens than monotherapy with SSG. Together, these results indicate that SSG resistance is associated with manipulation of both host and parasite GSH levels by L. donovani.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16377672      PMCID: PMC1346807          DOI: 10.1128/AAC.50.1.88-95.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  36 in total

1.  Long-distance genome walking using the long and accurate polymerase chain reaction.

Authors:  G S Min; J R Powell
Journal:  Biotechniques       Date:  1998-03       Impact factor: 1.993

2.  Macrophage protection by addition of glutathione (GSH)-loaded erythrocytes to AZT and DDI in a murine AIDS model.

Authors:  A Fraternale; A Casabianca; C Orlandi; A Cerasi; L Chiarantini; G Brandi; M Magnani
Journal:  Antiviral Res       Date:  2002-12       Impact factor: 5.970

3.  General suppression of macrophage gene expression during Leishmania donovani infection.

Authors:  S Buates; G Matlashewski
Journal:  J Immunol       Date:  2001-03-01       Impact factor: 5.422

4.  Sodium stibogluconate resistance in Leishmania donovani correlates with greater tolerance to macrophage antileishmanial responses and trivalent antimony therapy.

Authors:  K C Carter; S Hutchison; A Boitelle; H W Murray; S Sundar; A B Mullen
Journal:  Parasitology       Date:  2005-12       Impact factor: 3.234

5.  Plasmodium falciparum-infected red blood cells depend on a functional glutathione de novo synthesis attributable to an enhanced loss of glutathione.

Authors:  K Lüersen; R D Walter; S Müller
Journal:  Biochem J       Date:  2000-03-01       Impact factor: 3.857

6.  Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani.

Authors:  Susan Wyllie; Mark L Cunningham; Alan H Fairlamb
Journal:  J Biol Chem       Date:  2004-07-13       Impact factor: 5.157

7.  Measurement of the intracellular distribution of reduced glutathione in cultured rat hepatocytes using monochlorobimane and confocal laser scanning microscopy.

Authors:  D Stevenson; D Wokosin; J Girkin; M H Grant
Journal:  Toxicol In Vitro       Date:  2002-10       Impact factor: 3.500

8.  Plasmodium berghei: dehydroepiandrosterone sulfate reverses chloroquino-resistance in experimental malaria infection; correlation with glucose 6-phosphate dehydrogenase and glutathione synthesis pathway.

Authors:  Innocent Safeukui; François Mangou; Denis Malvy; Philippe Vincendeau; Djavad Mossalayi; Gilbert Haumont; Remi Vatan; Piero Olliaro; Pascal Millet
Journal:  Biochem Pharmacol       Date:  2004-11-15       Impact factor: 5.858

9.  Inhibition of influenza infection by glutathione.

Authors:  Jiyang Cai; Yan Chen; Shaguna Seth; Satoru Furukawa; Richard W Compans; Dean P Jones
Journal:  Free Radic Biol Med       Date:  2003-04-01       Impact factor: 7.376

10.  Inhibition of glutathione synthesis as a chemotherapeutic strategy for trypanosomiasis.

Authors:  B A Arrick; O W Griffith; A Cerami
Journal:  J Exp Med       Date:  1981-03-01       Impact factor: 14.307

View more
  17 in total

1.  Cross-resistance of Leishmania infantum isolates to nitric oxide from patients refractory to antimony treatment, and greater tolerance to antileishmanial responses by macrophages.

Authors:  Tatiana R de Moura; Micheli Luize Barbosa Santos; Juciene M Braz; Luis Felipe V C Santos; Matheus T Aragão; Fabricia A de Oliveira; Priscila L Santos; Ângela Maria da Silva; Amélia Ribeiro de Jesus; Roque P de Almeida
Journal:  Parasitol Res       Date:  2016-02       Impact factor: 2.289

2.  Profiling gene expression of antimony response genes in Leishmania (Viannia) panamensis and infected macrophages and its relationship with drug susceptibility.

Authors:  Maria Claudia Barrera; Laura Jimena Rojas; Austin Weiss; Olga Fernandez; Diane McMahon-Pratt; Nancy G Saravia; Maria Adelaida Gomez
Journal:  Acta Trop       Date:  2017-08-24       Impact factor: 3.112

Review 3.  Leishmania antimony resistance: what we know what we can learn from the field.

Authors:  Khatima Aït-Oudhia; Elodie Gazanion; Baptiste Vergnes; Bruno Oury; Denis Sereno
Journal:  Parasitol Res       Date:  2011-07-29       Impact factor: 2.289

4.  Leishmania donovani isolates with antimony-resistant but not -sensitive phenotype inhibit sodium antimony gluconate-induced dendritic cell activation.

Authors:  Arun Kumar Haldar; Vinod Yadav; Eshu Singhal; Kamlesh Kumar Bisht; Alpana Singh; Suniti Bhaumik; Rajatava Basu; Pradip Sen; Syamal Roy
Journal:  PLoS Pathog       Date:  2010-05-20       Impact factor: 6.823

5.  Frequency of drug resistance gene amplification in clinical leishmania strains.

Authors:  C Mary; F Faraut; M Deniau; J Dereure; K Aoun; S Ranque; R Piarroux
Journal:  Int J Microbiol       Date:  2010-07-12

6.  Modulation of gene expression in human macrophages treated with the anti-leishmania pentavalent antimonial drug sodium stibogluconate.

Authors:  Karima El Fadili; Michaël Imbeault; Nadine Messier; Gaétan Roy; Benjamin Gourbal; Marc Bergeron; Michel J Tremblay; Danielle Légaré; Marc Ouellette
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

7.  Gene expression profiling and molecular characterization of antimony resistance in Leishmania amazonensis.

Authors:  Rubens L do Monte-Neto; Adriano C Coelho; Frédéric Raymond; Danielle Légaré; Jacques Corbeil; Maria N Melo; Frédéric Frézard; Marc Ouellette
Journal:  PLoS Negl Trop Dis       Date:  2011-05-24

8.  Antimony resistance in leishmania, focusing on experimental research.

Authors:  Fakhri Jeddi; Renaud Piarroux; Charles Mary
Journal:  J Trop Med       Date:  2011-11-17

9.  Use of antimony in the treatment of leishmaniasis: current status and future directions.

Authors:  Arun Kumar Haldar; Pradip Sen; Syamal Roy
Journal:  Mol Biol Int       Date:  2011-06-08

Review 10.  Drug resistance in visceral leishmaniasis.

Authors:  Helena C Maltezou
Journal:  J Biomed Biotechnol       Date:  2009-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.